exhibit 10. 36 exhibit 10. 36 agreement between shandong yaobua medical instrument corporation and guided therapeutics, inc. confidential, final 24 july 2019 this agreement supersedes. any and all statements, representations or agreements other than existing purchase orders between guided therapeutics, inc, a georgia, united states of american corporation ( " gti') located at 5835 peachtree comers east, suite d, norcross, georgia 30092 and shan. dong yaohua medical instrument corporation, located at no. 5 zhuijian street, high - tech development zone, laiwu shandong, peoples republic of china ( " smi ). this agreement is dated 24 july 2019 whereas gti had previously asserted that they had developed a platform technology for the early detection of disease that leads to cancer ; whereas gti had previously asserted that their first non - invasive cancer detection product is the luviva® advanced cervical scan device ( the " device " ) and the related disposable cervical guides ( the " disposables " and, with the device. " luviva " ). luviva is designed to : gti – luviva ( device ). a. determine the true likelihood of treatable cervical disease that may lead to cancer in women aged 16 years and over who have been screened for cervical cancer and have an abnormal result b. be used as a screening tool both in the developed and developing world where papanicolau test and / or the human papilloma virus tests are not widely available whereas luviva is currently in use in canada, latin america, europe, turkey, asia and africa. whereas gti had previously asserted that they own the worldwide manufacturing, distribution and intellectual property ( " ip " ) rights to lu viva, and whereas gti asserts that they have the rights to license the global manufacturing rights, excepting the disposable cervical guides in the republic of turkey and final assembly rights of the device in hungary, and the rights to license the distribution and sales rights for luviva in the people's republic of china, macau, hong kong and taiwan ( herein after collectively referred to as the " jurisdictions " whereas smi is a medical device company in china with an established distribution and sales capability and bas indicated a capability and willingness to manufacture for the global market, and distribute and sell luviva in the jurisdictions, whereas smi, in order to obtain license to the license for global manufacturing